Inhibikase Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 14, 2025. The company recorded a net loss of $13.7 million, or $0.15 per share, for the quarter.
This represents a significant increase from the net loss of $4.6 million, or $0.73 per share, in the first quarter of 2024. Research and development expenses rose to $10.5 million, up from $2.8 million in the prior year period, including a $7.4 million non-cash charge for acquired in-process research and development associated with the CorHepta acquisition.
Selling, general and administrative expenses also increased to $5.2 million, compared to $2.0 million in the first quarter of 2024. As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $93.2 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.